Journal of Chemotherapy,
Год журнала:
2024,
Номер
unknown, С. 1 - 24
Опубликована: Дек. 22, 2024
Immunotherapy
has
been
advanced
through
multiple
approaches,
including
immunogenic
cytokines,
monoclonal
antibodies,
therapeutic
vaccinations,
adoptive
cell
transfer,
stem
transplantation,
and
oncolytic
viruses.
This
review
analyses
various
strategies
in
genomics,
transcriptomics,
single-cell
techniques,
computational
analysis,
big
data,
imaging
technologies
for
the
identification
of
tumour
microbiota
microenvironments.
is
becoming
acknowledged
as
a
feasible
cancer
treatment
method,
facilitating
innovative
medicines
personalized
medicine
techniques.
International Journal of Molecular Sciences,
Год журнала:
2024,
Номер
25(10), С. 5344 - 5344
Опубликована: Май 14, 2024
Osteosarcoma
is
a
type
of
bone
cancer
that
primarily
affects
children
and
young
adults.
The
overall
5-year
survival
rate
for
localized
osteosarcoma
70–75%,
but
it
only
20–30%
patients
with
relapsed
or
metastatic
tumors.
To
investigate
potential
glycan-targeting
structures
immunotherapy,
we
stained
primary
osteosarcomas
recombinant
C-type
lectin
CD301
(MGL,
CLEC10A)
observed
moderate
to
strong
staining
on
26%
the
NK92
cells
expressing
CD301-CAR
recognized
eliminated
in
vitro.
Cytotoxic
activity
assays
correlated
degranulation
cytokine
release
assays.
Combination
an
inhibitory
antibody
against
immune
checkpoint
TIGIT
(T-cell
immunoreceptor
lg
ITIM
domains)
showed
promising
additional
effects.
Overall,
this
study
showed,
first
time,
expression
ligands
tissue
demonstrated
their
use
as
target
lectin-based
immunotherapy.
Frontiers in Bioengineering and Biotechnology,
Год журнала:
2024,
Номер
12
Опубликована: Май 31, 2024
Efficient
engineering
of
T
cells
to
express
exogenous
tumor-targeting
receptors
such
as
chimeric
antigen
(CARs)
or
T-cell
(TCRs)
is
a
key
requirement
effective
adoptive
cell
therapy
for
cancer.
Genome
editing
technologies,
CRISPR/Cas9,
can
further
alter
the
functional
characteristics
therapeutic
through
knockout
genes
interest
while
knocking
in
synthetic
that
recognize
cancer
cells.
Performing
multiple
rounds
gene
transfer
with
precise
genome
editing,
termed
multiplexing,
remains
challenge,
especially
non-viral
delivery
platforms.
Here,
we
demonstrate
efficient
production
primary
human
incorporating
three
clinically
relevant
(
B2M
,
TRAC
and
PD1
)
along
transfection
CAR
targeting
disialoganglioside
GD2.
Multiplexed
results
high
on-target
deletion
all
genes,
low
off-target
chromosome
alterations.
Incorporating
knock
GD2-CAR
resulted
TRAC-B2M-PD1-deficient
GD2
product
central
memory
phenotype
cytotoxicity
against
GD2-expressing
neuroblastoma
target
gene-editing
by
CRISPR/Cas9
feasible
safe,
potential
rapid
manufacturing
highly
potent
allogeneic
products.
Internal Medicine,
Год журнала:
2024,
Номер
unknown
Опубликована: Янв. 1, 2024
Chimeric
antigen
receptor-T-cell
(CAR-T)
therapy
for
hematologic
malignancies
has
made
significant
advancements
over
the
years,
and
it
is
now
incorporated
as
a
treatment
algorithm.
Early
phase
clinical
trials
are
underway
various
solid
tumors,
effectiveness
of
CAR-T
cell
been
demonstrated
specific
types
glioma
several
tumors.
However,
its
efficacy
does
not
match
that
observed
in
hematological
malignancies.
Recently,
case
series
reported
targeting
CD19
autoimmune
diseases
such
systemic
lupus
erythematosus,
leading
to
dramatic
improvement
symptoms
possibility
discontinuing
immunosuppressive
agents.
Furthermore,
expected
be
effective
against
viruses
Aspergillus
spp.
Finally,
attempts
have
introduce
CAR
constructs
into
regulatory
T
cells
target
their
effects.
This
article
introduces
current
progress
beyond
only
discusses
future
directions,
considering
medical
situation
Japan.
International Journal of Research in Medical Sciences,
Год журнала:
2024,
Номер
12(12), С. 4829 - 4841
Опубликована: Ноя. 30, 2024
Chimeric
Antigen
Receptor
(CAR)-T
cell
therapy
has
recently
emerged
as
a
breakthrough
technology,
offering
targeted
approach
in
the
treatment
of
cancers.
It
is
form
cancer
immunotherapy
which
involves
genetic
modification
autogenic
or
allogenic
T
cells
to
express
chimeric
receptor
that
can
target
specific
tumor
antigen
on
malignant
cells.
The
receptors
are
because
both
antigen-binding
and
activating
functions
integrated
into
single
receptor.
greatest
potential
CAR-T
lies
its
power
use
patient’s
immune
system
fight
besides
durability.
also
overcomes
certain
limitations
such
limited
effectiveness
resistant
cancers,
lack
precision
blood
cancers
etc.
associated
with
traditional
therapies
like
chemotherapy
radiation.
proven
significantly
efficacious
clinical
trials
for
patients
relapsed
refractory
haematological
malignancies
lesser
extent
solid
tumors
too.
A
few
these
CAR-
have
finally
been
approved
by
FDA
after
decades
pre-clinical
developments.
though
causes
long
term
remissions
some
patients,
yet
either
relapse
suffer
severe
toxic
adverse
effects,
leaving
innovation
space
further
research.
This
review
discusses
structure
cells,
principle
applications,
efficacy,
safety,
challenges
future
directions
patients.
Journal of Chemotherapy,
Год журнала:
2024,
Номер
unknown, С. 1 - 24
Опубликована: Дек. 22, 2024
Immunotherapy
has
been
advanced
through
multiple
approaches,
including
immunogenic
cytokines,
monoclonal
antibodies,
therapeutic
vaccinations,
adoptive
cell
transfer,
stem
transplantation,
and
oncolytic
viruses.
This
review
analyses
various
strategies
in
genomics,
transcriptomics,
single-cell
techniques,
computational
analysis,
big
data,
imaging
technologies
for
the
identification
of
tumour
microbiota
microenvironments.
is
becoming
acknowledged
as
a
feasible
cancer
treatment
method,
facilitating
innovative
medicines
personalized
medicine
techniques.
